Amy E Pomeroy

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 14

Top Venues

Molecular cancer therapeutics

Blood cancer discovery

bioRxiv : the preprint server for biology

Science signaling

University of North Carolina at Chapel Hill (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

University of North Carolina at Chapel Hill Aug 15 2015

United States

PHD :: Bioinformatics and Computational Biology

North Carolina State University Aug 15 2011 - May 15 2015

United States

BSC :: Chemical and Biomolecular Engineering

Publications

Emily Mason-Osann, Amy E Pomeroy, Adam C Palmer, Jerome T Mettetal
SYNERGISTIC DRUG COMBINATIONS PROMOTE THE DEVELOPMENT OF RESISTANCE IN ACUTE MYELOID LEUKEMIA. Blood cancer discovery (2024)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. Molecular cancer therapeutics (2024)
Emily Mason-Osann, Amy E Pomeroy, Adam C Palmer, Jerome T Mettetal
SYNERGISTIC DRUG COMBINATIONS PROMOTE THE DEVELOPMENT OF RESISTANCE IN ACUTE MYELOID LEUKEMIA. Blood cancer discovery (2024)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. Molecular cancer therapeutics (2024)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive Response Explains the Benefit of Combination Chemotherapy Despite Drug Antagonism. Molecular cancer therapeutics 23 (7) (2024)
Emily Mason-Osann, Amy E Pomeroy, Adam C Palmer, Jerome T Mettetal
Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia. Blood cancer discovery 5 (2) (2024)
Emily Mason-Osann, Amy E Pomeroy, Adam C Palmer, Jerome T Mettetal
Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia. Blood cancer discovery 5 (2) (2024)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. Molecular cancer therapeutics (2024)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive Response Explains the Benefit of Combination Chemotherapy Despite Drug Antagonism. Molecular cancer therapeutics 23 (7) (2024)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. Molecular cancer therapeutics (2024)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. bioRxiv : the preprint server for biology (2023)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. bioRxiv : the preprint server for biology (2023)
Amy E Pomeroy, Matthew I Peña, John R Houser, Gauri Dixit, Henrik G Dohlman, Timothy C Elston, Beverly Errede
A predictive model of gene expression reveals the role of network motifs in the mating response of yeast. Science signaling 14 (670) (2021)
James P Shellhammer, Amy E Pomeroy, Yang Li, Lorena Dujmusic, Timothy C Elston, Nan Hao, Henrik G Dohlman
Quantitative analysis of the yeast pheromone pathway. Yeast (Chichester, England) 36 (8) (2019)

Amy E Pomeroy.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Amy E Pomeroy